---
title: Tumour Registry Colorectal Cancer
nct_id: NCT00910819
overall_status: COMPLETED
sponsor: iOMEDICO AG
study_type: OBSERVATIONAL
primary_condition: Colorectal Cancer
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00910819.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00910819"
ct_last_update_post_date: 2025-08-28
last_seen_at: "2026-05-12T06:30:25.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Tumour Registry Colorectal Cancer

**Official Title:** Prospective and Retrospective Observation of the Adjuvant and Palliative Treatment Strategies in the Therapy of Colorectal Cancer in Germany

**NCT ID:** [NCT00910819](https://clinicaltrials.gov/study/NCT00910819)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 7000
- **Lead Sponsor:** iOMEDICO AG
- **Collaborators:** Arbeitskreis Klinische Studien, Arbeitsgemeinschaft fur Internistische Onkologie
- **Conditions:** Colorectal Cancer
- **Start Date:** 2006-09
- **Completion Date:** 2022-03
- **CT.gov Last Update:** 2025-08-28

## Brief Summary

To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.

## Detailed Description

The TKK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of colorectal cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

The impact of nutrition (CoNut) and physical activity (CoNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (CoTox) and the final phase of the palliative process (CoLife). Based on the available data a prognostic score will be developed.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Colorectal cancer
* 18 years and older
* Antineoplastic treatment

Exclusion Criteria:

* No colorectal cancer
* Below 18 years
* No antineoplastic treatment
```

## Primary Outcomes

- **Course of Antineoplastic Treatment** _(time frame: 5 years)_

## Locations (1)

- iOMEDICO AG, Freiburg im Breisgau, Baden-Wurttemberg, Germany

## Recent Field Changes (last 30 days)

- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.iomedico ag|freiburg im breisgau|baden-wurttemberg|germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00910819.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00910819*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*